Literature DB >> 3257712

An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins.

M Till1, R D May, J W Uhr, P E Thorpe, E S Vitetta.   

Abstract

In this report, we describe an assay for screening monoclonal antibodies for their cytotoxic potential as ricin A chain-containing immunotoxins. The assay involves treating cells with dilutions of the test antibody followed by a Fab fragment of a secondary antibody coupled to ricin A chain ("indirect assay"). The cytotoxicity of the indirect assay is compared to that of the direct assay where the monoclonal antibody is coupled to ricin A chain. Indirect and direct assays were carried out using 14 antibodies and a panel of 8 human and mouse cell types. The two assays showed virtually 100% correlation. The indirect assay, therefore, predicts the potency of a given monoclonal antibody to make an effective immunotoxin and should be useful in screening monoclonal antibodies for use as immunotoxins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257712

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer.

Authors:  E J Wawrzynczak; E J Derbyshire; R V Henry; G D Parnell; A Smith; R Waibel; R A Stahel
Journal:  Br J Cancer Suppl       Date:  1991-06

2.  Monoclonal antibodies recognising the cluster 2 antigen associated with human small cell lung cancer mediate the toxic effects of ricin A chain in an indirect assay of immunotoxin cytotoxicity.

Authors:  E J Derbyshire; E J Wawrzynczak
Journal:  Br J Cancer Suppl       Date:  1991-06

Review 3.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

4.  Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.

Authors:  Seth H Pincus; Kejing Song; Grace A Maresh; Dean H Hamer; Dimiter S Dimitrov; Weizao Chen; Mei-Yun Zhang; Victor F Ghetie; Po-Ying Chan-Hui; James E Robinson; Ellen S Vitetta
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

Review 5.  Immunotoxins: new therapeutic reagents for autoimmunity, cancer, and AIDS.

Authors:  E S Vitetta
Journal:  J Clin Immunol       Date:  1990-11       Impact factor: 8.317

6.  Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain.

Authors:  M A Till; S Zolla-Pazner; M K Gorny; J S Patton; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

7.  Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates.

Authors:  D M Fishwild; H M Wu; S F Carroll; S L Bernhard
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate.

Authors:  P Casalini; M Caldera; S Canevari; S Ménard; D Mezzanzanica; E Tosi; M Gadina; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

9.  A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies.

Authors:  A Bolognesi; P L Tazzari; C Tassi; G Gromo; M Gobbi; F Stirpe
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

10.  Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.

Authors:  Ryan B Craig; Christopher M Summa; Miriam Corti; Seth H Pincus
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.